Department of Molecular Pharmacology, Shinshu University School of Medicine, Nagano, Japan.
Curr Eye Res. 2010 May;35(5):363-9. doi: 10.3109/02713680903518858.
It has been demonstrated that in patients with aponeurotic blepharoptosis, alpha(1)-adrenoceptor stimulation causes the contraction of the upper eyelid tarsal smooth muscle (Mueller's muscle) and opening of the eye. However, alpha(1)-adrenoceptor subtypes mediating the contraction of Mueller's muscle are still unclear. This study was designed to identify the alpha(1)-adrenoceptor subtypes in Mueller's muscle.
A newly developed canine upper eyelid preparation was retrogradely perfused with a drug-containing Krebs-Henseleit solution through the angular vein in a temperature-controlled organ chamber. The contraction of the preparation was measured with a force-displacement transducer.
Phenylephrine, an alpha(1)-adrenoceptor agonist, increased the upper eyelid contractile force in a dose-dependent manner (K(0.5) = 110 nmol). Interestingly, the contraction in response to phenylephrine was persistent and hardly recovered to a base line level for more than 100 min after washout of the drug. WB4101 (100 nM), an alpha(1A)- and alpha(1D)-adrenoceptor antagonist, but not BMY7378 (100 nM), a selective alpha(1D)-adrenoceptor antagonist, competitively inhibited the phenylephrine-induced contraction. ABT-866, a selective alpha(1A)-adrenoceptor agonist, increased the upper eyelid contractile force as effectively as phenylephrine in a dose-dependent manner (K(0.5) = 190 nmol), and the contraction continued again for more than 100 min.
These results suggest that selective alpha(1A)-adrenoceptor agonists, such as ABT-866, induce the sustained Mueller's muscle contraction and may be useful in pharmacological treatment of blepharoptosis.
已经证明,在腱膜性上睑下垂患者中,α1-肾上腺素受体刺激会引起上睑睑板平滑肌(Müller 肌)收缩和眼睛张开。然而,介导 Müller 肌收缩的α1-肾上腺素受体亚型仍不清楚。本研究旨在鉴定 Müller 肌中的α1-肾上腺素受体亚型。
通过角静脉在温度控制的器官室中向新开发的犬上眼睑制剂逆行灌注含有药物的 Krebs-Henseleit 溶液。制剂的收缩通过力位移传感器进行测量。
苯肾上腺素是一种α1-肾上腺素受体激动剂,可剂量依赖性地增加上睑收缩力(K0.5=110nmol)。有趣的是,苯肾上腺素引起的收缩在药物洗脱后持续存在,并且在 100 分钟以上几乎无法恢复到基线水平。WB4101(100nM),一种α1A-和α1D-肾上腺素受体拮抗剂,但不是 BMY7378(100nM),一种选择性α1D-肾上腺素受体拮抗剂,竞争性抑制苯肾上腺素诱导的收缩。ABT-866,一种选择性α1A-肾上腺素受体激动剂,以剂量依赖性方式有效地增加上睑收缩力(K0.5=190nmol),并且收缩再次持续 100 分钟以上。
这些结果表明,选择性α1A-肾上腺素受体激动剂,如 ABT-866,可引起持续的 Müller 肌收缩,可能对治疗上睑下垂具有药理学作用。